Radiation-Induced Lymphopoenia and Treatment Outcome in Hereditary Breast Cancer Patients
Open Access
- 1 January 2023
- journal article
- research article
- Published by Charles University in Prague, Karolinum Press in Folia Biologica
- Vol. 69 (3) , 91-98
Abstract
Many breast cancer (BC) predisposition genes encode proteins involved in DNA damage repair (DDR). Identification of germline pathogenic variants (PV) in DDR genes raises the question whether their presence can influence the treatment outcomes and potential radiation-induced toxicity in their carriers treated by adjuvant radiotherapy, which has not yet been answered conclusively. We retrospectively examined records of 213 BC patients treated by adjuvant radiotherapy, including 39 (18.3 %) BRCA1/2 PV carriers, 25 carriers (11.7 %) of PV in other breast cancer-predisposing genes, and 149 (70 %) non-carriers. Our goal was to examine 5-year disease-free survival (5y DFS) rates among the study groups and determine the impact of radiotherapy-induced lymphopoenia (RIL) on this outcome. While we found no significant difference in 5y DFS between non-carriers and carriers of BRCA mutations (86.4 % vs 78.4 % P = 0.24) or between non-carriers and other studied mutations (86.4 % vs 93.3 %; P = 0.27), respectively, we observed that the entire group of PV carriers had a significantly lower proportion of patients without RIL (P = 0.04) than the non-carriers. In contrast, subsequent analyses indicated a non-significant trend toward an increased 5y DFS in PV carriers with RIL. Our single-centre study indicated that the presence of PV in BC patients has an insignificant impact on DFS but can reduce the risk of RIL associated with adjuvant radiotherapy. It remains unclear whether this may result from the paradoxical activation of anti-tumour immunity in PV carriers with higher lymphocyte consumption resulting from higher immune effectiveness.Keywords
Funding Information
- Ministerstvo Zdravotnictví Ceské Republiky (00064165)
- Ministerstvo Zdravotnictví Ceské Republiky (NU20-03-00283)
- European Commission (LX22NPO5104)
This publication has 26 references indexed in Scilit:
- Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-CarriersCancers, 2019
- Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancerInternational Journal of Cancer, 2019
- RAD50 germline mutations are associated with poor survival in BRCA1/2–negative breast cancer patientsInternational Journal of Cancer, 2018
- Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromesPLOS ONE, 2018
- A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumorsCritical Reviews in Oncology/Hematology, 2018
- Women at high risk of breast cancer: Molecular characteristics, clinical presentation and managementThe Breast, 2016
- CZECANCA: CZEch CAncer paNel for Clinical Application – Design and Optimization of the Targeted Sequencing Panel for the Identification of Cancer Susceptibility in High-risk Individuals from the Czech RepublicKlinicka onkologie, 2016
- Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk AssessmentJAMA Oncology, 2015
- Radiotherapy in the Treatment of Hereditary Breast CancerSeminars in Radiation Oncology, 2011
- Clinical Radiation Sensitivity With DNA Repair Disorders: An OverviewInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009